• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自然杀伤 T 细胞淋巴瘤（NKTL）的发病机制和生物标志物。

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL).

机构信息

Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore.

Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore.

出版信息

J Hematol Oncol. 2019 Mar 15;12(1):28. doi: 10.1186/s13045-019-0717-6.

DOI:10.1186/s13045-019-0717-6
PMID:30876435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6420729/
Abstract

Natural killer T cell lymphoma (NKTL) is an aggressive disease with very poor treatment outcomes in the advanced stages. With chemotherapy, initial response rates to treatment are high but responses are short lived. A better understanding of the complex molecular pathogenesis of this disease is essential in order to design and develop better therapeutics with improved efficacy. This review aims to summarise the key pathogenic mechanisms in NKTL which may have significant prognostic and therapeutic implications.

摘要

自然杀伤 T 细胞淋巴瘤（NKTL）是一种侵袭性疾病，晚期治疗效果极差。尽管化疗初始反应率较高，但缓解时间短暂。为了设计和开发更有效的治疗方法，深入了解这种疾病复杂的分子发病机制至关重要。本文旨在总结 NKTL 中的关键发病机制，这些机制可能具有重要的预后和治疗意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f28b/6420729/128bbf62259e/13045_2019_717_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f28b/6420729/128bbf62259e/13045_2019_717_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f28b/6420729/128bbf62259e/13045_2019_717_Fig1_HTML.jpg

相似文献

1
Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL).自然杀伤 T 细胞淋巴瘤（NKTL）的发病机制和生物标志物。
J Hematol Oncol. 2019 Mar 15;12(1):28. doi: 10.1186/s13045-019-0717-6.
2
Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma.正电子发射断层扫描/计算机断层扫描在自然杀伤/T细胞淋巴瘤的诊断、分期及预后评估中的应用
J Int Med Res. 2018 Dec;46(12):4920-4929. doi: 10.1177/0300060518804375. Epub 2018 Oct 17.
3
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.异常的 JAK-STAT 信号转导介导的染色质重塑会损害 NK/T 细胞淋巴瘤对沙利度胺的敏感性。
Clin Epigenetics. 2023 Feb 6;15(1):19. doi: 10.1186/s13148-023-01436-6.
4
Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma.鼻腔和韦氏环自然杀伤/ T细胞淋巴瘤的临床症状多样。
Clin Cancer Res. 2009 Apr 15;15(8):2905-12. doi: 10.1158/1078-0432.CCR-08-2914. Epub 2009 Mar 24.
5
Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.超级增强子驱动的 TOX2 在自然杀伤/T 细胞淋巴瘤中介导肿瘤发生。
Mol Cancer. 2023 Apr 10;22(1):69. doi: 10.1186/s12943-023-01767-1.
6
Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.探讨与侵袭性 NK 细胞白血病和慢性活动性 EBV 感染相关淋巴组织增生性疾病的关系，分析与年龄相关的 EBV 相关结外 NK/T 细胞淋巴瘤患者的临床病理差异。
Histopathology. 2011 Oct;59(4):660-71. doi: 10.1111/j.1365-2559.2011.03976.x.
7
Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.通过基因表达谱分析揭示的结外鼻型 NK/T 细胞淋巴瘤中的激活致癌途径和治疗靶点。
J Pathol. 2011 Mar;223(4):496-510. doi: 10.1002/path.2823. Epub 2011 Jan 5.
8
The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.热休克蛋白90抑制剂格尔德霉素通过下调Akt诱导爱泼斯坦-巴尔病毒阳性NK/T细胞淋巴瘤的凋亡性细胞死亡。
J Pathol. 2007 Oct;213(2):170-9. doi: 10.1002/path.2219.
9
Management of extranodal natural killer/t-cell lymphoma, nasal type.鼻型结外自然杀伤/T细胞淋巴瘤的管理
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):245-52. doi: 10.1016/j.clml.2014.12.014. Epub 2015 Jan 3.
10
The factors associated with the early diagnosis of nasal NK/T-cell lymphoma with prominent ocular symptoms and general nasal NKTL.与以眼部症状和一般鼻部 NKTL 为突出表现的鼻腔 NK/T 细胞淋巴瘤的早期诊断相关的因素。
Am J Otolaryngol. 2019 May-Jun;40(3):353-357. doi: 10.1016/j.amjoto.2019.01.012. Epub 2019 Jan 28.

引用本文的文献

1
Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.慢性髓性白血病经酪氨酸激酶抑制剂治疗后的继发性恶性肿瘤：人群趋势与结局
Br J Haematol. 2025 Sep;207(3):834-841. doi: 10.1111/bjh.20226. Epub 2025 Jul 7.
2
Metabolic parameter of baseline 18 F-FDG PET/CT with PINK models improve the prediction of treatment outcome in extranodal NK/T-cell lymphoma treated with P-GEMOX chemotherapy.基于PINK模型的基线18F-FDG PET/CT代谢参数可改善接受P-GEMOX化疗的结外NK/T细胞淋巴瘤治疗结果的预测。
Ann Hematol. 2025 Feb;104(2):1069-1078. doi: 10.1007/s00277-025-06243-y. Epub 2025 Feb 11.
3

本文引用的文献

1
Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map.从组织修复中寻找治疗癌症的新靶点——利用 STAT3 活性
Nat Rev Cancer. 2019 Feb;19(2):82-96. doi: 10.1038/s41568-018-0090-8.
2
Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.结外自然杀伤/T 细胞淋巴瘤中 EBV 的基因组和转录组图谱。
Leukemia. 2019 Jun;33(6):1451-1462. doi: 10.1038/s41375-018-0324-5. Epub 2018 Dec 13.
3
Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma.
Butyrate-producing suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway.
产生丁酸盐通过抑制JAK-STAT信号通路来抑制自然杀伤/T细胞淋巴瘤。
Gut. 2025 Mar 6;74(4):557-570. doi: 10.1136/gutjnl-2024-333530.
4
Molecular significance of circRNAs in malignant lymphoproliferative disorders: pathogenesis and novel biomarkers or therapeutic targets.环状RNA在恶性淋巴增殖性疾病中的分子意义：发病机制及新型生物标志物或治疗靶点
Am J Cancer Res. 2024 Sep 25;14(9):4633-4651. doi: 10.62347/KMWB5164. eCollection 2024.
5
Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.结外 NK/T 细胞淋巴瘤突变谱分析：临床与预后相关性研究。
Ann Hematol. 2024 Aug;103(8):2917-2930. doi: 10.1007/s00277-024-05698-9. Epub 2024 Apr 27.
6
Novel target and treatment agents for natural killer/T-cell lymphoma.自然杀伤/T 细胞淋巴瘤的新型靶标和治疗药物。
J Hematol Oncol. 2023 Jul 22;16(1):78. doi: 10.1186/s13045-023-01483-9.
7
Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma.强效选择性STAT3抑制剂WB737在自然杀伤/T细胞淋巴瘤中的临床前特征分析
MedComm (2020). 2023 Jun 16;4(4):e284. doi: 10.1002/mco2.284. eCollection 2023 Aug.
8
Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.超级增强子驱动的 TOX2 在自然杀伤/T 细胞淋巴瘤中介导肿瘤发生。
Mol Cancer. 2023 Apr 10;22(1):69. doi: 10.1186/s12943-023-01767-1.
9
The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins.从一对双胞胎患者中鉴定结外 NK/T 细胞淋巴瘤的基因特征。
BMC Cancer. 2021 Dec 6;21(1):1303. doi: 10.1186/s12885-021-09023-9.
10
CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3.环状ADARB1作为自然杀伤T细胞淋巴瘤的一种新生物标志物以及p-Stat3的潜在调节因子。
Cancer Cell Int. 2021 Nov 4;21(1):594. doi: 10.1186/s12935-021-02296-x.
全外显子组测序鉴定出家族性NK/T细胞淋巴瘤中FAM160A1基因的隐性胚系突变。
Blood Cancer J. 2018 Nov 12;8(11):111. doi: 10.1038/s41408-018-0149-5.
4
Frequent Mutations in Natural Killer/T Cell Lymphoma.自然杀伤/ T细胞淋巴瘤中的常见突变
Cell Physiol Biochem. 2018;49(1):1-16. doi: 10.1159/000492835. Epub 2018 Aug 22.
5
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.致癌激活 STAT3 通路驱动自然杀伤/T 细胞淋巴瘤中 PD-L1 的表达。
Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.
6
The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.自然杀伤/T 细胞淋巴瘤的基因组学和分子生物学：转化的机会。
Int J Mol Sci. 2018 Jun 30;19(7):1931. doi: 10.3390/ijms19071931.
7
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.致癌激活 JAK3-STAT 信号赋予了新型选择性和强效 JAK3 抑制剂 PRN371 在自然杀伤/T 细胞淋巴瘤中的临床敏感性。
Leukemia. 2018 May;32(5):1147-1156. doi: 10.1038/s41375-017-0004-x. Epub 2018 Feb 2.
8
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.帕博利珠单抗治疗复发/难治性 NK/T 细胞淋巴瘤的疗效。
J Hematol Oncol. 2018 Jan 31;11(1):15. doi: 10.1186/s13045-018-0559-7.
9
Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.一名转移性、化疗/放疗耐药卵巢癌患者携带 PD-L1 基因重排，对派姆单抗治疗有显著反应。
Clin Cancer Res. 2018 Jul 15;24(14):3282-3291. doi: 10.1158/1078-0432.CCR-17-1805. Epub 2018 Jan 19.
10
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.低剂量纳武单抗阻断程序性死亡蛋白1用于对左旋门冬酰胺酶治疗失败的NK/T细胞淋巴瘤：疗效与安全性
Ann Hematol. 2018 Jan;97(1):193-196. doi: 10.1007/s00277-017-3127-2. Epub 2017 Sep 6.